# Article information:

B7-H3/CD276: An Emerging Cancer Immunotherapy - PMC
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326801/>

# Article summary:

1. B7-H3/CD276 is an emerging cancer immunotherapy that has been studied for its potential to enhance antitumor immunity.

2. The article discusses the role of B7-H3 in tumor immunity, including its costimulatory and coinhibitory roles, as well as its regulation of T cell responses and metabolic signalling programmes.

3. The article also examines the potential of B7-H3 as a target for cancer immunotherapy, exploring its effects on tumor growth and angiogenesis, as well as its involvement in medulloblastoma growth and invasion.

# Article rating:

Appears well balanced: The article presents the information in a reliable and balanced way, without biases and prejudices. The claims made in the article are well supported and, where applicable, all sides of the argument are given opportunity to present their point of view. The article appears trustworthy and reliable.

# Article analysis:

The article “B7-H3/CD276: An Emerging Cancer Immunotherapy” is a comprehensive review of the current research on the role of B7-H3/CD276 in cancer immunotherapy. The authors provide an overview of the various roles that B7-H3 plays in tumor immunity, including costimulation and coinhibition, regulation of T cell responses and metabolic signalling programmes, and effects on tumor growth and angiogenesis. The article is based on a thorough review of relevant literature from peer-reviewed journals, with citations provided for each source used.

The article does not appear to be biased or one-sided; it presents both sides of the argument fairly by discussing both the potential benefits and risks associated with using B7-H3/CD276 as a target for cancer immunotherapy. Furthermore, all claims made are supported by evidence from scientific studies cited throughout the paper. There are no missing points or counterarguments that have been overlooked; instead, all relevant information is presented in detail. Additionally, there is no promotional content or partiality present in the article; it provides an unbiased overview of current research on this topic without any attempts to sway readers towards any particular conclusion or opinion. Finally, possible risks associated with using B7-H3/CD276 are noted throughout the paper; these include potential side effects such as inflammation or autoimmunity due to overstimulation of immune cells by this molecule.

In conclusion, this article appears to be reliable and trustworthy due to its comprehensive coverage of relevant literature on this topic and lack of bias or promotional content.

# Topics for further research:

* B7-H3/CD276 cancer immunotherapy clinical trials
* B7-H3/CD276 cancer immunotherapy safety
* B7-H3/CD276 cancer immunotherapy efficacy
* B7-H3/CD276 cancer immunotherapy mechanisms
* B7-H3/CD276 cancer immunotherapy side effects
* B7-H3/CD276 cancer immunotherapy combination therapies

# Report location:

<https://www.fullpicture.app/item/86d59f2e8dbaa8f986a6ff200d45ca80>